|Bid||123.31 x 1400|
|Ask||124.99 x 1000|
|Day's range||123.19 - 124.33|
|52-week range||87.68 - 132.30|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||46.33|
|Forward dividend & yield||2.52 (2.02%)|
|Ex-dividend date||24 Jun 2021|
|1y target est||N/A|
Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF), a pioneer in the transformation of spinal surgery through artificial intelligence, predictive modeling and patient specific implants, today announced that they have entered into a tender offer agreement for the acquisition of all outstanding shares of Medicrea. The friendly voluntary all-cash tender offer will be at a price of €7.00 per Medicrea share (the "Tender Offer"). The Boards of Directors of both companies have unanimously approved the transaction.
Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.